Showing results (61-70 of 128) with videos related to

Sort By:
Pageof 13
Journal of Hepatology|March 1, 2011
Clinical features and evolution of alveolar echinococcosis in France from 1982 to 2007: results of a survey in 387 patientsMartine Piarroux, Renaud Piarroux, Roch Giorgi, et al.
Journal of Hepatology|June 5, 2002
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon aloneVictor de Lédinghen, Pascale Trimoulet, Maria Winnock, et al.
European Journal of Gastroenterology & Hepatology|October 19, 2004
Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosisArmand Abergel, Claude Darcha, Michèle Chevallier, et al.
Gastroenterology|July 20, 2010
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirinMark G Swain, Ming-Yang Lai, Mitchell L Shiffman, et al.
Plos One|January 29, 2019
Prospective evaluation of a dynamic insulin infusion algorithm for non critically-ill diabetic patients: A before-after studyNathanaëlle Montanier, Lise Bernard, Céline Lambert, et al.
Minerva Gastroenterology|February 11, 2022
Noninvasive biomarkers of non-alcoholic fatty liver disease in patients with metabolic syndrome: insights from the RESOLVE StudyGaël Ennequin, Benjamin Buchard, Bruno Pereira, et al.
Clinics and Research in Hepatology and Gastroenterology|September 14, 2024
Effect of different modalities of exercise on Fatty Liver Index in patients with metabolic syndrome: The RESOLVE randomized trialAlexis Couret, James A King, Bruno Pereira, et al.
Transplantation|October 28, 2017
Does Portopulmonary Hypertension Impede Liver Transplantation in Cirrhotic Patients? A French Multicentric Retrospective StudyMaud Reymond, Louise Barbier, Ephrem Salame, et al.
Health Science Reports|December 8, 2022
An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir-grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study)Jean-Pierre Bronowicki, Patrick Miailhes, Bertrand Hanslik, et al.
The Lancet. Gastroenterology & Hepatology|November 6, 2018
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trialTarik Asselah, Samuel S Lee, Betty B Yao, et al.
Pageof 13